Teprotumumab (Tepezza): Uses, Dosage, Side Effects, Warnings - Drugs.com
Dec 3, 2024 · Teprotumumab (Tepezza) is used for thyroid eye disease (TED) to help reduce eye bulging (proptosis), improve redness, pain, and swelling of the eyes, and improve double vision (diplopia).
Teprotumumab - Wikipedia
Teprotumumab, sold under the brand name Tepezza, is a medication used to treat adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge outwards.
Teprotumumab for the Treatment of Active Thyroid Eye Disease
Jan 22, 2020 · In the current trial (OPTIC), we investigated the efficacy and safety of teprotumumab, an IGF-IR inhibitor, as compared with placebo in patients with clinically active thyroid eye disease.
TEPEZZA® (teprotumumab-trbw) | Thyroid Eye Disease Treatment
TEPEZZA® (teprotumumab-trbw) is a prescription medicine for the treatment of Thyroid Eye Disease (TED), also known as Graves' Orbitopathy. See safety information.
Teprotumumab - EyeWiki
Teprotumumab is a fully human monoclonal antibody that targets the insulin-like growth factor 1 (IGF-1) receptor (IGF-1R). It was approved by the FDA in January 2020 for the treatment of thyroid eye disease. [1]
Teprotumumab - StatPearls - NCBI Bookshelf
Sep 4, 2023 · Teprotumumab is a newly approved medication to manage active, moderate to severe thyroid eye disease. Teprotumumab has been approved by the U.S. Food and Drug Administration (FDA) for treating thyroid orbitopathy, under breakthrough therapy designation, as an Orphan Drug.
Tepezza: Uses, Dosage, Side Effects, Warnings - Drugs.com
Dec 16, 2024 · Tepezza (teprotumumab) is an inhibitor of insulin-like growth factor-1 receptor (IGF-1R) used to treat Thyroid Eye Disease (TED). It is a monoclonal antibody that blocks IGF-1R activation and signaling.
Teprotumumab (Tepezza) for Thyroid Eye Disease - PMC
Teprotumumab is currently the only Federal Drug Administration approved therapy for the treatment of TED. Significant improvements in proptosis, diplopia and quality of life are noted following its 24-week course of therapy.
Teprotumumab: A Review in Thyroid Eye Disease - PMC
Teprotumumab (TEPEZZA ®), a monoclonal antibody that inhibits the insulin-like growth factor 1 receptor (IGF-1R), is the first disease-modifying therapy approved for the treatment of thyroid eye disease (TED) in the USA.
TEPEZZA® (teprotumumab-trbw) TED Treatment | HCP Home
Have you heard about TEPEZZA® (teprotumumab-trbw), the first and only FDA-approved treatment for this rare, chronic autoimmune condition? See clinical trial results, view the safety profile, and get your patients started here.